MA49716A - Incorporation de nucléotides non naturels et procédés d'utilisationin vivo - Google Patents
Incorporation de nucléotides non naturels et procédés d'utilisationin vivoInfo
- Publication number
- MA49716A MA49716A MA049716A MA49716A MA49716A MA 49716 A MA49716 A MA 49716A MA 049716 A MA049716 A MA 049716A MA 49716 A MA49716 A MA 49716A MA 49716 A MA49716 A MA 49716A
- Authority
- MA
- Morocco
- Prior art keywords
- incorporation
- vivo
- procedures
- natural nucleotides
- nucleotides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
- C12P19/28—N-glycosides
- C12P19/30—Nucleotides
- C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/07—Nucleotidyltransferases (2.7.7)
- C12Y207/07007—DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762531329P | 2017-07-11 | 2017-07-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA49716A true MA49716A (fr) | 2021-04-07 |
Family
ID=65002437
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA049716A MA49716A (fr) | 2017-07-11 | 2018-07-10 | Incorporation de nucléotides non naturels et procédés d'utilisationin vivo |
Country Status (4)
Country | Link |
---|---|
US (1) | US20200224234A1 (fr) |
EP (1) | EP3651774A4 (fr) |
MA (1) | MA49716A (fr) |
WO (1) | WO2019014262A1 (fr) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016531122A (ja) | 2013-08-08 | 2016-10-06 | ザ スクリップス リサーチ インスティテュートThe Scripps Research Institute | 非天然ヌクレオチドの取り込みによるインビトロの核酸の部位特異的な酵素標識のための方法 |
TWI638047B (zh) | 2014-04-09 | 2018-10-11 | 史基普研究協會 | 藉由核酸三磷酸酯轉運子將非天然或經修飾的核苷三磷酸酯輸入至細胞中 |
US11761007B2 (en) | 2015-12-18 | 2023-09-19 | The Scripps Research Institute | Production of unnatural nucleotides using a CRISPR/Cas9 system |
DK3475295T3 (da) | 2016-06-24 | 2022-10-24 | Scripps Research Inst | Hidtil ukendt nukleosidtriphosphat-transportør og anvendelser deraf |
TWI821192B (zh) | 2017-07-11 | 2023-11-11 | 美商新索思股份有限公司 | 非天然核苷酸之導入及其方法 |
CN114949240A (zh) | 2019-02-06 | 2022-08-30 | 新索思股份有限公司 | Il-2缀合物及其使用方法 |
KR20220034109A (ko) | 2019-06-14 | 2022-03-17 | 더 스크립스 리서치 인스티튜트 | 반합성 유기체의 복제, 전사 및 번역을 위한 시약 및 방법 |
CA3150163A1 (fr) | 2019-08-15 | 2021-02-18 | Synthorx, Inc. | Polytherapies immuno-oncologiques avec des conjugues d'il-2 |
AU2020337869A1 (en) | 2019-08-23 | 2022-03-03 | Synthorx, Inc. | IL-15 conjugates and uses thereof |
TW202124385A (zh) | 2019-09-10 | 2021-07-01 | 美商欣爍克斯公司 | 治療自體免疫疾病之il-2接合物及使用方法 |
JP2022549931A (ja) * | 2019-09-30 | 2022-11-29 | ザ スクリプス リサーチ インスティテュート | 真核生物の半合成生物 |
TW202128996A (zh) * | 2019-10-10 | 2021-08-01 | 美商史基普研究協會 | 用於活體內合成非天然多肽的組合物及方法 |
MX2022005251A (es) | 2019-11-04 | 2022-06-08 | Synthorx Inc | Conjugados de interleuquina 10 y sus usos. |
US11827880B2 (en) | 2019-12-02 | 2023-11-28 | Shape Therapeutics Inc. | Therapeutic editing |
CN116209465A (zh) | 2020-06-25 | 2023-06-02 | 新索思股份有限公司 | 用il-2缀合物与抗egfr抗体的免疫肿瘤学组合疗法 |
IL301611A (en) | 2020-10-09 | 2023-05-01 | Synthorx Inc | Combined immuno-oncology treatment with pairs of IL-2 and pembrolizumab |
EP4225375A1 (fr) | 2020-10-09 | 2023-08-16 | Synthorx, Inc. | Thérapies immuno-oncologiques avec des conjugués d'il-2 |
WO2022174101A1 (fr) | 2021-02-12 | 2022-08-18 | Synthorx, Inc. | Polythérapie contre le cancer de la peau à l'aide de conjugués il-2 et de cemiplimab |
TW202302148A (zh) | 2021-02-12 | 2023-01-16 | 美商欣爍克斯公司 | 使用il-2接合物和抗pd-1抗體或其抗原結合片段的肺癌組合療法 |
WO2022256534A1 (fr) | 2021-06-03 | 2022-12-08 | Synthorx, Inc. | Polythérapie contre le cancer de la tête et du cou comprenant un conjugué d'il-2 et du pembrolizumab |
JP2024525866A (ja) | 2021-07-16 | 2024-07-12 | アプター バイオ,インク. | 遺伝子発現を調節するためのポリヌクレオチド組成物および方法 |
WO2023122573A1 (fr) | 2021-12-20 | 2023-06-29 | Synthorx, Inc. | Polythérapie contre le cancer de la tête et du cou comprenant un conjugué d'il-2 et du pembrolizumab |
WO2023122750A1 (fr) | 2021-12-23 | 2023-06-29 | Synthorx, Inc. | Polythérapie contre le cancer avec des conjugués d'il-2 et du cétuximab |
WO2024136899A1 (fr) | 2022-12-21 | 2024-06-27 | Synthorx, Inc. | Thérapie anticancéreuse avec des conjugués d'il-2 et des thérapies par récepteur antigénique chimérique |
GB202406362D0 (en) | 2024-05-07 | 2024-06-19 | Phytoform Labs Ltd | Solanaceae plants having altered morphology |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016531122A (ja) * | 2013-08-08 | 2016-10-06 | ザ スクリップス リサーチ インスティテュートThe Scripps Research Institute | 非天然ヌクレオチドの取り込みによるインビトロの核酸の部位特異的な酵素標識のための方法 |
TWI638047B (zh) * | 2014-04-09 | 2018-10-11 | 史基普研究協會 | 藉由核酸三磷酸酯轉運子將非天然或經修飾的核苷三磷酸酯輸入至細胞中 |
US11761007B2 (en) * | 2015-12-18 | 2023-09-19 | The Scripps Research Institute | Production of unnatural nucleotides using a CRISPR/Cas9 system |
DK3475295T3 (da) * | 2016-06-24 | 2022-10-24 | Scripps Research Inst | Hidtil ukendt nukleosidtriphosphat-transportør og anvendelser deraf |
TWI821192B (zh) * | 2017-07-11 | 2023-11-11 | 美商新索思股份有限公司 | 非天然核苷酸之導入及其方法 |
-
2018
- 2018-07-10 US US16/629,211 patent/US20200224234A1/en active Pending
- 2018-07-10 EP EP18832929.6A patent/EP3651774A4/fr active Pending
- 2018-07-10 MA MA049716A patent/MA49716A/fr unknown
- 2018-07-10 WO PCT/US2018/041503 patent/WO2019014262A1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
WO2019014262A1 (fr) | 2019-01-17 |
EP3651774A1 (fr) | 2020-05-20 |
US20200224234A1 (en) | 2020-07-16 |
EP3651774A4 (fr) | 2021-07-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA49716A (fr) | Incorporation de nucléotides non naturels et procédés d'utilisationin vivo | |
MA49578A (fr) | Incorporation de nucléotides non naturels et procédés associés | |
MA46427A (fr) | Compositions d'oligonucléotides et procédés associés | |
MA43822A (fr) | Compositions et procédés de synthèse de phosphoramidite et d'oligonucléotides | |
ZA201704976B (en) | Oral care compositions and methods of use | |
MA50636A (fr) | Compositions et procédés pour inhiber l'activité d'arginase | |
MA42269A (fr) | Compositions et procédés d'inhibition de l'activité de l'arginase | |
IL257663B (en) | Oral treatment compounds and methods of using them | |
MA45688A (fr) | Compositions et procédés de potentialisation d'agents antimicrobiens | |
ZA201807359B (en) | Oral care compositions and methods of use | |
ZA201903432B (en) | Oral care compositions and methods of use | |
ZA201801012B (en) | Oral care compositions and methods of use | |
MA45290A (fr) | Procédés et compositions d'agents biologiquement actifs | |
MA51430A (fr) | Compositions de paire de bases non naturelles et procédés d'utilisation | |
MA42685A (fr) | Synthèse de chlorhydrate de lévométhadone ou de chlorhydrate de dextrométhadone et leurs méthodes d'utilisation | |
SG11201912185XA (en) | Three dimensional tissue compositions and methods of use | |
MA46586A (fr) | Compositions de terlipressine et leurs procédés d'utilisation | |
ZA201902268B (en) | Oral care compositions and methods of use | |
MA54412A (fr) | Traitement d'excès de graisse hépatique et/ou viscérale | |
MA43730A (fr) | Malassezine et analogues correspondants en tant qu'agents d'éclaircissement de la peau | |
EP2707486A4 (fr) | Diagnostic et traitement de l'ataxie de friedreich | |
MA42497A (fr) | Procédés et compositions pour la régulation sélective de l'expression protéique | |
MA50829A (fr) | Exclusion d'exon induite pat technologie antisens dans le collagène de type vii | |
IT201700085412A1 (it) | Composizione per uso nella prevenzione e nel trattamento di patologie dell'apparato cardiovascolare | |
MA43178A (fr) | Analogues d'épothilone, procédés de synthèse, procédés de traitement, et conjugués médicamenteux de ceux-ci |